Table 4

Number (%) of patients with prior treatment of a biologic agent

Rheumatoid arthritis

Ankylosing spondylitis

Psoriatic arthritis

Psoriasis

Other a

Total


N [N missing]

188 [3]

43 [0]

44 [0]

35 [0]

19 [12]

329 [15]

No prior treatment

127 (67.6%)

28 (65.1%)

30 (68.2%)

24 (68.6%)

15 (78.9%)

224 (68.1%)

Unsure of prior treatment

24 (12.8%)

5 (11.6%)

6 (13.6%)

4 (11.4%)

1 (5.3%)

40 (12.2%)

Any prior treatment

37 (19.7%)

10 (23.3%)

8 (18.2%)

7 (20.0%)

3 (15.8%)

65 (19.8%)

Adalimumab

31 (16.5%)

5 (11.6%)

7 (15.9%)

2 (5.7%)

3 (15.8%)

48 (14.6%)

Infliximab

7 (3.7%)

4 (9.3%)

0 (0.0%)

1 (2.9%)

0 (0.0%)

12 (3.6%)

Anakinra

2 (1.1%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

2 (0.6%)

Abatacept

0 (0.0%)

1 (2.3%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (0.3%)

Rituximab

3 (1.6%)

1 (2.3%)

1 (2.3%)

0 (0.0%)

0 (0.0%)

5 (1.5%)

Efalizumab

1 (0.5%)

0 (0.0%)

0 (0.0%)

4 (11.4%)

0 (0.0%)

5 (1.5%)


a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?'

Wade et al. BMC Medical Research Methodology 2011 11:91   doi:10.1186/1471-2288-11-91

Open Data